* Ligand Pharmaceuticals Inc reported quarterly adjusted earnings of $1.84​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.02. The mean expectation of eight analysts for the quarter was for earnings of $1.35 per share. Wall Street expected results to range from $1.17 to $1.68 per share.

* Revenue rose 57.6% to $51.81 million from a year ago; analysts expected $40.65 million.

* Ligand Pharmaceuticals Inc's reported EPS for the quarter was a loss of 39 cents​.

* The company reported a quarterly loss of $7.17 million.

* Ligand Pharmaceuticals Inc shares had risen by 16.8% this quarter and gained 63.7% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 2.8% in the last three months.​

* In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Ligand Pharmaceuticals Inc is $129.00 This summary was machine generated from LSEG data November 7 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 1.35 1.84 Beat

Jun. 30 2024 1.40

Mar. 31 2024 0.78 1.20 Beat

Dec. 31 2023 0.66 1.38 Beat